Home
stock market
news
These are the 25 stocks to bet against on a successful COVID-19 vaccine, according to JPMorgan

These are the 25 stocks to bet against on a successful COVID-19 vaccine, according to JPMorgan

Matthew Fox

With a successful COVID-19 vaccine on the horizon, some stocks may fare better than others.
According to JPMorgan, investors should look to bet against a handful of stocks that have experienced increased momentum in their business amid the COVID-19 pandemic.
Once a successful COVID vaccine is distributed and administered, it could lead to a slowdown in growth for a number of businesses as a return to normal activity ensues.
Here are 25 stocks traders should bet against once a successful COVID-19 vaccine is disbursed, according to JPMorgan.
Visit Business Insider's homepage for more stories.

The development of a successful COVID-19 vaccine could have wide-ranging implications on a basket of stocks that saw a surge in growth amid the pandemic.

That's according to a Friday note from JPMorgan, which put together a list of 25 stocks traders should bet against once a COVID-19 vaccine is distributed and administered to the population.

"This is a list of stocks that are in the upper echelon of Momentum and have crowded positioning, that could see the second derivative of their profit growth decrease as consumer/corporate activity normalizes," JPMorgan explained.

On the flip side, Goldman Sachs offered six stocks on Friday that could benefit from the distribution and administration of a successful COVID-19 vaccine.

The JPMorgan basket of stocks should be viewed as a tactical opportunity to express a bearish view on the catalyst of a COVID-19 vaccine, and should not be viewed as a fundamental call on the company.

Here are 25 stocks traders should bet against once a successful COVID-19 vaccine is disbursed, according to JPMorgan.

1. Novavax

YTD Performance: 2190%

2. Zoom Video

YTD Performance: 654%

3. Overstock.com

YTD Performance: 887%

4. Fiverr International

YTD Performance: 583%

5. Peloton Interactive

YTD Performance: 338%

6. Moderna